Reata’s pivotal data in Friedreich ataxia point to submissions

Days after regaining worldwide rights to omaveloxolone, Reata announced plans to submit regulatory applications in the U.S. and other territories for the compound in Friedreich ataxia based on newly released pivotal trial data.

Reata Pharmaceuticals

Read the full 348 word article

How to gain access

Continue reading with a
two-week free trial.